Announced Tue, 7 Jul · 16:20 IST
Investor Presentation for June 2026 filed with exchanges
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+2.0%1-day move
₹1902.70
prior close
₹1904.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.0+1.1+1.2+0.4+2.0+1.6+1.0+2.1+2.6+1.6————
Up moveDown movePending
AI summary
Sun Pharma filed its June 2026 investor presentation with exchanges. FY26 sales grew 11.9 percent to Rs 582.2 Bn, EBITDA up 16.1 percent at Rs 177.3 Bn with 30.3 percent margin. Adjusted net profit Rs 124 Bn (up 3.5 percent). India formulations lead at 33 percent of revenues, US at 29 percent. Market cap Rs 4,460 Bn. R&D spend Rs 35.5 Bn (6.1 percent of sales). Targets mid-to-high single digit topline growth.
Likely market impact
Detailed financials and growth strategy shared. EBITDA margin improved to 30.3 percent. Forward guidance targets mid-to-high single digit topline growth.